Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/20160
標題: 玻尿酸合成酶第一型及相關訊息傳遞分子 的表現與上泌尿道移行上皮細胞癌的局部 復發及轉移有關
Expression of Hyaluronic Acid Synthase-1 Related Signal Transduction Molecules Correlate Cancer Local Recurrence and Distant Metastases in Upper Urinary Tract Transitional Cell Carcinoma
作者: 李建儀
Li, Jian-Ri
關鍵字: Hyaluronic acid synthase-1;玻尿酸合成酶移行上皮細胞癌;transitional cell carcinoma;upper urinary tract;上泌尿道
出版社: 醫學科技研究所
引用: Adamia S. (2005) Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Augustine A. (1988) Bladder cancer in relation to cigarette smoking. Black P.C. (2007) Targeted therapies in bladder cancer--an update. Blute M.L. (1989) Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. Boffetta P. (2007) Chromosomal aberrations and cancer risk: results of a cohort study from Central Europe. Bourguignon L.Y. (2001) Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. Bourguignon L.Y. (2007) Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. Bourguignon L.Y. (2007) Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. Brenner D.W. (1987) Upper tract urothelial malignancy after cyclophosphamide therapy: A case report and literature review. Burch J.D. (1989) Risk of bladder cancer by source and type of tobacco exposure: A case-control study. Camenisch T.D. (2000) Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. Caoili E.M. (2002) Urinary tract abnormalities: Initial experience with multi-detector row CT urography. Carroll P.R. (1995) Urothelial carcinoma: cancers of the bladder, ureter and renal pelvis. In: Tanagho EA and McAninch JW, Editors, General Urology (14th ed.), Prentice-Hall, Philadelphia. Department of Health, Executive Yuan, Republic of China, Taiwan, R.O.C. (2009) Cancer Registry Annual Report (2006), Republic of China. Godec C.J. (1985) Simultaneous occurrence of transitional cell carcinoma and urothelial adenocarcinoma associated with xanthogranulomatous pyelonephritis. Golshani R. (2008) Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Goodison S. (1999) CD44 cell adhesion molecules. Götte M. (2006). Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Grinnell F. (2008) Fibroblast mechanics in three-dimensional collagen matrices. Grossman H.B. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. Hall M.C. (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Igawa M. (1995) Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Jensen O.M. (1988) The Copenhagen case-control study of renal pelvis and ureter cancer: Role of smoking and occupational exposures. Johnson P. (2000) A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response? Ju M.K. (2009) Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience. Kao J.J. (2006) The NF-kappaB inhibitor pyrrolidine dithiocarbamate blocks IL-1beta induced hyaluronan synthase 1 (HAS1) mRNA transcription, pointing at NF-kappaB dependence of the gene HAS1. Kosaki R. (1999) Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Li W.M. (2009) The Prognostic Predictors of Primary Ureteral Transitional Cell Carcinoma After Radical Nephroureterectomy. Liou S.H. (1999) Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Liu N. (2001) Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Lower Jr. G.M. (1979) N-Acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology: Preliminary results in Sweden and Denmark. Lynch H.T. (1990) The Lynch syndrome II and urological malignancies. McCredie M. (1986) Phenacetin and papillary necrosis. Independent risk factors for renal pelvic cancer. McLaughlin J.K. (1992) Cigarette smoking and cancers of the renal pelvis and ureter. Misra S. (2008) Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. Morrison A.S. (1976) Epidemiology of bladder cancer. Morrison A.S. (1984) Advances in the etiology of urothelial cancer. Noble P.W. (2002) Hyaluronan and its catabolic products in tissue injury and repair. Nocks B.N. (1982) Transitional cell carcinoma of renal pelvis. Nortier J.L. (2000) Urothelial carcinomaassociated with the use of a Chinese herb (Aristolochia fangchi). Petkovic S.D. (1975) Epidemiology and treatment of renal pelvic and ureteral tumors. Radovanovic Z. (1985) Family history of cancer among cases of upper urothelial tumours in the Balkan nephropathy area. Rassweiler J.J. (2004) Laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: is it better than open surgery? Rehn L. (1895) Ueber ueblasentrumoren bei fuchsinarbeiten. Ressequie L.T. (1978) Epidemiology of renal and ureteral cancer in Rochester, Minnesota, 1950-1974, with special reference to clinical and pathologic features. Roscigno M. (2009) Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Ross R.K. (1989) Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Saito K. (2007) Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. Spicer A.P. (1998) Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. Spruck C.H. (1993) Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Stadler W.M. (1993) Molecular events in the initiation and progression of bladder cancer. Steffens J. (1988) Tumours of the renal pelvis and ureter. Observations in 170 patients. Steineck G. (1990) Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Tan L.B. (2008) Clinical and epidemiological featureres of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. Thompson R.H. (2008) Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Turley E.A. (2002) Signaling properties of hyaluronan receptors. Vanherweghem J.L. (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Waldert M. (2009) The oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy. Wu C.F. (2007) The Impact Factors on Prognosis of Patients With pT3 Upper Urinary Tract Transitional Cell Carcinoma. Wu M.J. (2004) High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Yabushita H. (2004) Hyaluronan synthase expression in ovarian cancer. Yabushita H. (2005) Role of hyaluronan and hyaluronan synthase in endometrial cancer. Yang M.H. (2002) Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan.
摘要: 
Background & Aims: Hyaluronic acid synthase type 1(HAS-1) was considered a key enzyme in the tumor proliferation and migration. We investigate the potential association between HAS-1 and clinical tumor grade, stage, chemotherapy response, tumor metastases and local recurrence. The molecular biologic cancer proliferation and migration pathway through HAS-1 was also studied. Methods: From January 2008 to March 2009, a total 32 patients who have urothelial carcinoma and received nephroureterectomy or cystectomy were enrolled. We analyzed the HAS-1 and CD44 mRNA expression of the tumor samples using the polymerase chain reaction (PCR). The clinical stage, tumor grading, angiolymphatic invasion, existence of carcinoma in situ, development of distant metastases or local recurrence were collected. We also selected urothelial carcinoma cell lines T24, TSGH, TCCSUP, RT4, 5637, J82 to investigate the correlation between cell proliferation, migration and HAS-1 expression. The possible pathway of cell proliferation through HAS-1 was studied. Results: HAS-1 mRNA PCR showed overexpression in high grade and high clinical stage tissue samples. Recurrence developed in those whose tumor tissue HAS-1 overexpression without adjuvant chemotherapy. CD44 mRNA did not showed overexpression among these tissues. In the cell line study, HAS-1 overexpression was not found. CD44 and VEGF overexpression were observed in T24 and J82 cell line and the the cell motility were also better in these two cell lines. Conclusions: HAS-1 expression combined with clinical pathological stage could offer better decision making in the adjuvant chemotherapy. Downstream CD44 and related markers need more data to support the signal transduction pathway. In cell line studies, the bladder cancer proliferation and migration pathway may correlate with the hypothetic key factor, CD44. T24 and J82 cell lines showed much more malignant behavior and were suitable for further studies.

背景目的: 玻尿酸合成酶第一型(HAS-1)被認為是腫瘤生長及轉移時的一個重要的酵素,目前對於玻尿酸形成酶第一型在上泌尿道移行上皮細胞癌的表現與應用仍不明,因此我們分析上泌尿道移行上皮細胞癌中HAS-1及其相關訊號分子的表現,並研究與臨床腫瘤分級、分期、淋巴腺轉移、淋巴血管侵犯、化學治療反應及復發與轉移的影響。方法:從2008年1月到2009年3月,我們搜集了32位因為移行上皮細胞癌接受腎臟或膀胱根除患者的腫瘤檢體,利用聚合酵素連鎖反應分析腫瘤的mRNA表現,並與臨床腫瘤分級、分期、淋巴腺轉移、淋巴血管侵犯、化學治療反應及復發與轉移來比較差異。此外,我們取6株膀胱的移行上皮細胞癌細胞株,T24、TSGH、TCCSUP、RT4、5637及J82,使用MTS細胞抑殺試驗來進行細胞生長分析,用Transwell chamber 侵襲試驗來研究癌細胞的侵襲和運動能力。結果: HAS-1在高惡性度的組織中呈現過量表現,並且腫瘤分期愈晚期,過量表達的比例愈高,臨床上HAS-1呈現過量表現的高分期患者,若未接受化學治療,則必定發生轉移,而腫瘤組織中的CD44則未發現有過量表現的情形。在膀胱移行上皮細胞癌細胞株的實驗中,並未發現有HAS-1的過量表現,但是可見CD44及VEGF在較惡性的T24及J82中過度表現,並可觀察出腫瘤細胞的運動能力增加。結論: 併用HAS-1與臨床分期可以協助作為術後輔助化學治療的指標,CD44等下游指標仍待進一步研究,但極可能是重要的細胞癌化的關鍵,T24及J82將可採用來進行後續的實驗。
URI: http://hdl.handle.net/11455/20160
其他識別: U0005-2108200900013500
Appears in Collections:生物醫學研究所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.